Compare Booz Allen Hamilton Holding Corporation (BAH) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Enveric Biosciences Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $77.75 (market cap $9.45B), while Enveric Biosciences Inc trades at $1.58 (market cap $6.20M). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 1524.2× Enveric Biosciences Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| BAH | ENVB | |
|---|---|---|
Market Cap | $9.45B | $6.20M |
Sector | Industrials | Health |
52-Week High | $111.63 | $17.40 |
52-Week Low | $59.71 | $1.27 |
Enterprise Value | $13.07B | $1.30M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.9, up 2.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 7.01% net margin and 68.11% ROE, supported by $11.98B revenue in 2025. Analysts maintain a Buy consensus with a $84.67 price target, citing government contracts and AI investments as growth drivers, though debt levels and civil revenue weakness pose concerns.
The outlook for BAH is positive due to consistent earnings outperformance and strategic focus on national security and cybersecurity. Investment appeal lies in its discounted valuation (P/E 12.33) and dividend yield, but risks include high leverage (debt-to-asset 54.67%) and reliance on government spending, which could impact growth if budget pressures arise.
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
